Related Experiment Video

Updated: Jul 9, 2026

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii
11:37

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

A PDR5-independent pathway of multi-drug resistance regulated by the SIN4 gene product

A Fleckenstein1, J Shallom, J Golin

  • 1Department of Biology, Catholic University of America, Washington, DC 20064, USA.

Yeast (Chichester, England)
|February 25, 1999
PubMed

Insights

Loss of function mutations in the SIN4 gene cause yeast hypersensitivity to multiple drugs. This drug resistance pathway is distinct from the PDR5-mediated pathway, revealing two separate mechanisms for substrate resistance in yeast.

Area of Science:

  • * Molecular Biology
  • * Yeast Genetics
  • * Drug Resistance Mechanisms

Background:

  • * The SIN4 locus in yeast encodes a global transcriptional regulator impacting numerous genes.
  • * Understanding transcriptional regulation is key to deciphering cellular responses to environmental stress, including drug exposure.

Purpose of the Study:

  • * To investigate the role of the SIN4 gene in yeast drug resistance.
  • * To determine if SIN4-mediated drug resistance is linked to the known PDR5 pathway.

Main Methods:

  • * Analysis of yeast strains with loss-of-function mutations in the SIN4 gene.
  • * Comparative drug sensitivity assays on single sin4 mutants, pdr5 mutants, and double sin4 pdr5 mutants.
  • * Examination of SIN4's regulatory influence on the PDR5 locus.

Main Results:

  • * Loss of SIN4 function results in a multi-drug hypersensitive phenotype in yeast.
  • * This hypersensitivity is independent of PDR5-mediated resistance, as double mutants show greater sensitivity than single mutants.
  • * SIN4 was found not to regulate the PDR5 locus.

Conclusions:

  • * Yeast possess at least two genetically distinct pathways that confer resistance to similar drug substrates.
  • * The SIN4 gene represents a novel component in a drug resistance pathway separate from PDR5.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...